Table 2 Baseline clinical characteristics of all patients, and patients discriminated with the presence of late gadolinium enhancement (LGE) and segmental wall motion abnormality (SWMA)
All patients (n = 86) | LGE negative (n = 25) | LGE positive (n = 61) | p-value | SWMA negative (n = 30) | SWMA positive (n = 56) | p-value | |
|---|---|---|---|---|---|---|---|
Demographics | |||||||
Age, year | 53 (42–61) | 49 (42–59) | 53 (42–63) | 0.278 | 51 (42–59) | 53 (42–62) | 0.336 |
Gender, female | 39 (45) | 15 (60) | 24 (39) | 0.131 | 20 (67) | 19 (34) | 0.007 |
Cardiovascular risk factors | |||||||
Dyslipidemia | 51 (59) | 14 (56) | 37 (61) | 0.871 | 17 (57) | 34 (61) | 0.893 |
Hypertension | 34 (40) | 7 (28) | 27 (44) | 0.247 | 10 (33) | 24 (43) | 0.529 |
Diabetes | 7 (8) | 2 (8) | 5 (8) | 1.000 | 0 (0) | 7 (13) | 0.108 |
Smoking | 19 (22) | 6 (24) | 13 (21) | 1.000 | 6 (20) | 13 (23) | 0.944 |
Family risk for CAD | 11 (13) | 5 (20) | 6 (10) | 0.285 | 5 (17) | 6 (11) | 0.504 |
Sum of risk factors | 1 (1–2) | 1 (0–2) | 1 (1–2) | 0.513 | 1 (1–2) | 1 (1–2) | 0.406 |
Symptoms | |||||||
Syncope or presyncope | 21 (24) | 9 (36) | 12 (20) | 0.185 | 9 (30) | 12 (21) | 0.536 |
Palpitation | 34 (40) | 13 (52) | 21 (34) | 0.204 | 14 (47) | 20 (36) | 0.448 |
Chest pain | 31 (36) | 9 (36) | 22 (36) | 1.000 | 12 (40) | 19 (34) | 0.746 |
NYHA-class | 2 (1–3) | 1 (1–2) | 2 (1–4) | 0.001 | 1 (1–2) | 2 (1–4) | 0.001 |
Congestive heart failure | 38 (44) | 4 (16) | 34 (56) | 0.002 | 2(7) | 36 (64) | < 0.001 |
Arrhythmias | |||||||
Atrial fibrillation | 25 (29) | 6 (24) | 19 (31) | 0.688 | 5 (17) | 20 (36) | 0.109 |
Ventricular fibrillation | 9 (10) | 3 (12) | 6 (10) | 0.715 | 3 (10) | 6 (11) | 1.000 |
Sustained VT | 9 (10) | 1 (4) | 8 (13) | 0.274 | 1 (3) | 8 (14) | 0.152 |
Nonsustained VT | 16 (19) | 6 (24) | 10 (16) | 0.542 | 5 (17) | 11 (20) | 0.962 |
Conducting abnormalities | |||||||
AVB of any grade | 39 (45) | 7 (28) | 32 (53) | 0.067 | 9 (30) | 30 (54) | 0.062 |
Distal AVB | 7 (8) | 3 (12) | 4 (7) | 0.409 | 3 (10) | 4 (7) | 0.691 |
Cardiac enzyme elevation* | 32 (37) | 8 (32) | 24 (39) | 0.693 | 9 (30) | 23 (41) | 0.436 |